• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans
  • .org
  • Districts
  • Media
  • SupportUs
  • Collaborate
  • Contact
  • Search
  • Join


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

Assorted News (RegMed)

Started by caliban , Feb 19 2011 03:26 AM
regenerative medicine tissue engineering stemcells regmed

  • Please log in to reply
178 replies to this topic

#121 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 01 November 2012 - 06:41 PM

RegMed Sector: 10 things you should know of … this morning
Proactive Investors USA & Canada - 1 hour ago
Worth Knowing … BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation appointed Francois Binette, PhD, as OrthoCyte's Vice President of Research and Business Development.

View the full article

#122 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 01 November 2012 - 06:35 PM

Geron (GERN) Q3 Highlights and Achievements
Proactive Investors USA & Canada - 1 hour ago
Not a bad year but, not totally a good year … Comments re BioTime (NYSE MKT: BTX) from the conference call: I'd <Dr . John Scarlett, CEO> also like to provide a brief update regarding the potential divestiture of the stem cell programs.

View the full article

#123 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 02 November 2012 - 02:20 PM

Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer
FierceBiotech - 2 hours ago
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

View the full article

sponsored ad

  • Advert

#124 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 31 October 2012 - 01:31 PM

Geron Posts Narrower Loss - Analyst Blog
NASDAQ - Oct 31, 2012
Geron Corporation ( GERN ) posted a net loss of 13 cents per share in the third quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 16 cents.

View the full article

#125 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 05 November 2012 - 03:01 PM

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San ...
Reuters - 14 minutes ago
By Ivan Deryugin. When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market.

View the full article

#126 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 05 November 2012 - 03:01 PM

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San ...
Reuters - 3 hours ago
By Ivan Deryugin. When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market.

View the full article

#127 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 01 November 2012 - 06:35 PM

Geron (GERN) Q3 Highlights and Achievements
Proactive Investors USA & Canada - Nov 1, 2012
Not a bad year but, not totally a good year … Comments re BioTime (NYSE MKT: BTX) from the conference call: I'd <Dr . John Scarlett, CEO> also like to provide a brief update regarding the potential divestiture of the stem cell programs.

View the full article

#128 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 06 November 2012 - 10:45 PM

RegMed sector co-exists in the down market
Proactive Investors USA & Canada - 3 hours ago
End of Day, Cause and Effect … RegMed stocks pulled back across the board Friday, as weakness trumped a better-than-expected monthly government jobs report amid nervousness ahead of the presidential election next week.

View the full article

#129 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 07 November 2012 - 03:19 PM

Five Regenerative Medicine Companies Worthy of Portfolio Addition
Equities.com - 56 minutes ago
Five Regenerative Medicine Companies Worthy of Portfolio Addition. Baystreet.ca. Category: Baystreet Newswire. Company: Emerging Growth Corp.

View the full article

#130 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 07 November 2012 - 01:51 PM

BIOTIME, INC. : BioTime and Subsidiary Cell Cure Neurosciences Ltd ...
4-traders - 2 hours ago
BioTime, Inc. : BioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing. 11/07/2012| 08:50am US/Eastern. BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

View the full article

#131 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 07 November 2012 - 03:19 PM

Five Regenerative Medicine Companies Worthy of Portfolio Addition
Equities.com - Nov 7, 2012
Five Regenerative Medicine Companies Worthy of Portfolio Addition. Baystreet.ca. Category: Baystreet Newswire. Company: Emerging Growth Corp.

View the full article

#132 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 09 November 2012 - 03:27 PM

Investor Caution: Indentifying the Next Penny Stocks (AMD, ALU, GERN, MTG ...
24/7 Wall St. - 1 hour ago
Some companies are in real trouble. Some are under severe industry pressure, and some are just faltering due to missteps and bad luck.

View the full article

#133 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 09 November 2012 - 11:14 PM

BioTime Q3 loss widens – Quick Facts
RTT News - 1 hour ago
BioTime Inc. (BTX: Quote) reported that its third-quarter net loss attributable to the company was $5.0 million or $0.10 per share, compared to a net loss of $3.7 million or $0.08 per share for the same period of 2011.

View the full article

#134 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 09 November 2012 - 10:36 PM

BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate ...
The Herald | HeraldOnline.com - 1 hour ago
ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 ...

View the full article

#135 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 09 November 2012 - 10:02 PM

RegMed sector, lackluster Friday as markets settle down
Proactive Investors USA & Canada - 2 hours ago
The 6 W's: Who, what, where, when, why and what of it … The RegMed sector's choppy trading comes as traders digest the sell-off that was seen over the past 2 days, which reflected concerns about the cash positions, development achievements and ...

View the full article

#136 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 11 November 2012 - 09:00 PM

BRIEF: BioTime invests 3.5m in Cell Cure through share swap
MENAFN.COM - 45 minutes ago
BRIEF: BioTime invests 3.5m in Cell Cure through share swap. Nov 11, 2012 (Menafn - Globes - McClatchy-Tribune Information Services via COMTEX) --Cell Cure Neurosciences Ltd.

View the full article

#137 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 09 November 2012 - 10:36 PM

BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate ...
The Herald | HeraldOnline.com - Nov 9, 2012
ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 ...

View the full article

#138 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 12 November 2012 - 02:09 PM

BIOTIME, INC. : Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure ...
4-traders - 1 hour ago
BioTime, Inc. : Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure Neurosciences Ltd. Receives Additional Financing From BioTime Inc. 11/12/2012| 09:05am US/Eastern.
BRIEF: BioTime invests 3.5m in Cell Cure through share swap - MENAFN.COM

View the full article

#139 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 13 November 2012 - 04:47 PM

Largest NYSE Alternext Short Interest Positions as of Oct. 31
Businessweek - 2 hours ago
Skills Gap: No Big Deal, If—€¦ · B-School Startups: Fulfilling a Dream With Ashesi University · One Year With Solar Energy at Home: Mostly Sunny.

View the full article

#140 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 12 November 2012 - 02:04 PM

Hadasit Bio-Holdings Ltd. Portfolio Company Cell Cure Neurosciences Ltd ...
PR Newswire (press release) - Nov 12, 2012
JERUSALEM, Nov. 12, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical ...

View the full article

#141 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 13 November 2012 - 04:46 PM

Largest NYSE Alternext Short Interest Positions as of Oct. 31
Bloomberg - 20 hours ago
Largest NYSE Alternext Short Interest Positions as of Oct. 31. By Bloomberg News - 2012-11-13T16:24:28Z. The following are the 100 largest short interest positions on the NYSE Alternext as of the Oct. 31 settlement date.

View the full article

#142 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 14 November 2012 - 02:05 PM

BIOTIME, INC. : BioTime and Subsidiary LifeMap Sciences Announce the ...
4-traders - 2 hours ago
BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents? Portal. 11/14/2012| 09:05am US/Eastern.
BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap ... - MarketWatch (press release)

View the full article

#143 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 15 November 2012 - 11:08 PM

StreetInsider.com After-Hours Movers 11/15: (SHF) (ARUN) (GPS) Higher ...
StreetInsider.com (subscription) - 37 minutes ago
Schiff Nutrition International, Inc. (NYSE: SHF) 29% HIGHER; Reckitt Benckiser to acquire the company for $42.00 per share in cash valuing Schiff at approximately $1.4 billion.

View the full article

#144 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 17 November 2012 - 06:20 AM

Geron to sell embryonic stem cell business to BioTime
San Francisco Business Times (blog) - 55 minutes ago
Geron Corp. will sell its shuttered embryonic stem cell assets to BioTime Inc., according to a non-binding letter of intent signed by the companies.

View the full article

#145 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 14 November 2012 - 02:05 PM

BIOTIME, INC. : BioTime and Subsidiary LifeMap Sciences Announce the ...
4-traders - Nov 14, 2012
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents? (http://bioreagents.

View the full article

#146 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 16 November 2012 - 05:41 PM

Geron-BioTime Sign LOI - Analyst Blog
NASDAQ - Nov 16, 2012
A year after announcing its decision to exit stem cell therapy, Geron Corporation ( GERN ) announced that it has entered into a non-binding letter of intent (LOI) with BioTime, Inc. ( BTX ) and BioTime`s subsidiary, BioTime Acquisition Corporation (BAC ...

View the full article

#147 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 15 November 2012 - 10:01 PM

Geron Announces Non-Binding Letter of Intent with BioTime Regarding Stem ...
Reuters - Nov 15, 2012
MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed subsidiary, BioTime ...

View the full article

#148 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 15 November 2012 - 09:42 PM

BIOTIME, INC. : BioTime and BioTime Acquisition Corporation Announce ...
4-traders - Nov 15, 2012
BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private investor to provide ...

View the full article

#149 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 19 November 2012 - 04:28 PM

LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards ...
DailyFinance - 2 hours ago
(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.09, on November 18, 2012.

View the full article

#150 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 15 November 2012 - 09:20 PM

BIOTIME, INC. : BioTime Announces Non-Binding Letter of Intent with Geron ...
4-traders - Nov 15, 2012
BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation.

View the full article
Back to Ventures & Markets



Also tagged with one or more of these keywords: regenerative medicine, tissue engineering, stemcells, regmed

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users

  1. LONGECITY
  2. → Round Table Discussion
  3. → Business
  4. → Ventures & Markets
  5. site rules